Alzheimer's Disease Clinical Trial
— MARAEOfficial title:
Alzheimer's Disease and Physiological, Cognitive Function and BDNF Levels of Plasma Adaptation After Exercise Training
NCT number | NCT02968875 |
Other study ID # | 15/B/03 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | July 2015 |
Est. completion date | February 2018 |
Verified date | May 2018 |
Source | University Hospital Center of Martinique |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Alzheimer's disease (AD) is a neurodegenerative disease leading to one of the most common forms of dementia in humans and memory disorder is one of the first symptoms that lead to diagnosis.
Status | Completed |
Enrollment | 54 |
Est. completion date | February 2018 |
Est. primary completion date | December 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility |
Inclusion Criteria: - Alzheimer's disease patients diagnosed by a consultation memory (DSM- IV) - Person with at least 60 years - Person with a score higher than 15 in the Mini Mental State Examination - No one can achieve the pedaling motion - People who do not perform regular physical activity on bike - Nobody has given free and informed consent in writing or obtained from a trusted person or the family environment - People affiliated to a social security Exclusion Criteria: - Patient who refused to provide written consent - Inability to pedal - Recent myocardial necrosis (less than 3 months) - Aortic Stenosis - Uncompensated heart failure - Unstable angina - Ventricular arrythmia - Pulmonary embolism - Coxarthrosis, knee, ankle osteoarthritis - Not affiliated to a social security - Patient already participating in another biomedical research |
Country | Name | City | State |
---|---|---|---|
Martinique | CHU de Martinique | Fort-de-France |
Lead Sponsor | Collaborator |
---|---|
University Hospital Center of Martinique |
Martinique,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Measuring the effect of a program of endurance training (ET), on the levels of plasma BDNF. | Up to 4 months | ||
Secondary | Measuring the effect of training on the psychological performance by using questionnaire MMSE | Up to 4 months | ||
Secondary | Measuring the effect of training on the psychological performance by using questionnaire: Rey auditory verbal learning test (RAVLT) | Up to 4 months | ||
Secondary | Measuring the effect of training on the psychological performance by using questionnaire: quality of life (QoL-AD) | Up to 4 months | ||
Secondary | Stress test | Measuring the effect of training on the physiological performance by determining the maximum power of the effort tolerated | Up to 4 months | |
Secondary | Stress test | Measuring the effect of training on the physiological performance by determining the grip strength | Up to 4 months | |
Secondary | Measuring the effect of training on the physiological performance with a walk test of 6 minutes. | Up to 4 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Withdrawn |
NCT03316898 -
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
|
Phase 1 | |
Withdrawn |
NCT02860065 -
CPC-201 Alzheimer's Disease Type Dementia: PET Study
|
Phase 2 | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Recruiting |
NCT05607615 -
A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease
|
Phase 2 | |
Terminated |
NCT03307993 -
Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease
|
Phase 1 | |
Recruiting |
NCT02912936 -
A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease
|
N/A | |
Active, not recruiting |
NCT02899091 -
Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT02868905 -
Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women
|
N/A | |
Completed |
NCT02907567 -
Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease
|
Phase 1/Phase 2 | |
Terminated |
NCT02521558 -
Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease
|
N/A | |
Completed |
NCT02516046 -
18F-AV-1451 Autopsy Study
|
Phase 3 | |
Completed |
NCT02580305 -
SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
|
Phase 2 | |
Recruiting |
NCT02247180 -
Cognitive Rehabilitation in Alzheimer`s Disease
|
N/A | |
Completed |
NCT02260167 -
Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol
|
N/A | |
Completed |
NCT02256306 -
The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study
|
N/A | |
Completed |
NCT02317523 -
Alzheimer's Caregiver Coping: Mental and Physical Health
|
N/A | |
Terminated |
NCT02220738 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
|
Phase 1 | |
Completed |
NCT01920672 -
Disrupted Sleep, Neuroendocrine Status and the Behavioral Symptoms of AD
|
N/A |